Disease · EFO_0005940
psychotic symptoms
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. psychotic symptoms. Diseases, record EFO_0005940. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0005940
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- psychotic symptoms
- Open Targets ID
- EFO_0005940
- Highest stage of its drugs
- Phase 3, for 6 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DONEPEZIL | CHEMBL502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PALIPERIDONE PALMITATE | CHEMBL2107360 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RALOXIFENE | CHEMBL81 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TROSPIUM | CHEMBL1888176 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| XANOMELINE | CHEMBL21536 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/1268 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha agonist; Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 3 | https://conductscience.org/library/genes/43 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 1 | Muscarinic acetylcholine receptor M1 agonist | Phase 3 | https://conductscience.org/library/genes/1128 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 antagonist | Phase 3 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Phase 3 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CHRM4 | Muscarinic acetylcholine receptor M4 | 1 | Muscarinic acetylcholine receptor M4 agonist | Phase 3 | https://conductscience.org/library/genes/1132 | Drugs and targets |
| ESR2 | Estrogen receptor beta | 1 | Estrogen receptor beta modulator | Phase 3 | https://conductscience.org/library/genes/2100 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01193153 | A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder | Phase 3 | 667 | 2015-01-05 | Schizoaffective Disorder | PALIPERIDONE PALMITATE | Its record names the disease | ClinicalTrials.gov |
| NCT01696929 | An Open-Label Trial of Tocilizumab in Schizophrenia | Phase 1 | 8 | 2015-10-07 | Schizophrenia | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00034762 | Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease | Phase 3 | 473 | Dementia, Alzheimer Disease, Mental Disorders | RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03043820 | Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder | Phase 3 | 110 | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS | RALOXIFENE | Its record names the disease | ClinicalTrials.gov | |
| NCT00206570 | Clinical Estradiol Trial in Women With Schizophrenia | Phase 2 | 100 | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder | ESTRADIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00190021 | Donepezil Treatment of Psychotic Symptoms in Dementia Patients | Phase 3 | 80 | Dementia of Alzheimer Type | DONEPEZIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04605393 | Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study | Not applicable | 36 | Schizophrenia, Cannabis Use | CANNABIDIOL, DRONABINOL | Its record names the disease | ClinicalTrials.gov | |
| NCT03826563 | Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms | Not applicable | 21 | Psychosis, Sleep | MELATONIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07084831 | A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia | Phase 3 | 0 | Schizophrenia; Psychosis, Cognitive Impairment | TROSPIUM, XANOMELINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0005940
GET https://conductscience.org/api/diseases/v1/EFO_0005940/drugs